Frances Zipp, President & CEO of Lachman Consultants who provides expert guidance to the pharmaceutical, biologic and biotechnology industries. Ms. Zipp joined Lachman after a 30-year career in the industry, where she held significant positions of responsibility for Quality and GxP Compliance, including various positions in drug development, operations, quality and regulatory affairs. Ms. Zipp delivers the strategic guidance and direction toward implementation of effective solutions to client needs. As an expert in compliance enhancement, she develops program solutions to meet GxP compliance requirements and works with industry senior management to restore healthy company relationships with regulatory authorities. Ms. Zipp has extensive experience covering the gamut of R&D through post-marketing surveillance. She assists and counsels senior-level management in areas of Corporate Governance, Corporate Integrity Agreement Compliance, Consent Decree Negotiations and Resolutions, Application Integrity Policy resolution, Due Diligence evaluations (facilities; products; technologies), and provides leadership, direction and management of the Lachman consulting operations as well as Corporate services including Legal and Financial services and administration.